PSEN1 Presenilin 1 AD Causal Chain

PSEN1 Presenilin 1 AD Causal Chain

Overview

This synthesis page documents the complete causal chain from PSEN1 (Presenilin 1) genetic mutations to Alzheimer's disease phenotype, integrating genetic evidence, molecular mechanisms, cellular pathways, and therapeutic intervention points.

Genetic Evidence

PSEN1 Gene Overview

PSEN1 encodes Presenilin 1, the catalytic subunit of the gamma-secretase complex. It is the most common cause of autosomal dominant early-onset Alzheimer's disease (EOAD).

| Property | Value |
|----------|-------|
| Chromosome | 14q24.3 |
| Protein | Presenilin 1 (467 amino acids) |
| Function | Aspartyl protease, gamma-secretase catalytic subunit |
| Inheritance | Autosomal dominant |
| Age of Onset | Typically 30-60 years (mean ~45) |

Key Pathogenic Mutations

Over 300 pathogenic mutations in PSEN1 have been identified. The most well-characterized include:

| Mutation | Location | Effect | Year Described |
|----------|----------|--------|----------------|
| M146L | TM2 | γ-secretase hyperactivity | 1995 |
| L286V | TM7 | Aβ42/40 ratio increase | 1998 |
| A246E | TM6 | Altered APP processing | 1996 |
| H163Y | TM4 | Increased Aβ42 | 1997 |
| L173W | TM4 | Impaired gamma-secretase | 2001 |
| C410Y | PALM | Loss of function | 2004 |
| P436S | PALM | Impaired autophagy | 2018 |

Genetic Evidence Score: 10/10

PSEN1 Presenilin 1 AD Causal Chain

Overview

This synthesis page documents the complete causal chain from PSEN1 (Presenilin 1) genetic mutations to Alzheimer's disease phenotype, integrating genetic evidence, molecular mechanisms, cellular pathways, and therapeutic intervention points.

Genetic Evidence

PSEN1 Gene Overview

PSEN1 encodes Presenilin 1, the catalytic subunit of the gamma-secretase complex. It is the most common cause of autosomal dominant early-onset Alzheimer's disease (EOAD).

| Property | Value |
|----------|-------|
| Chromosome | 14q24.3 |
| Protein | Presenilin 1 (467 amino acids) |
| Function | Aspartyl protease, gamma-secretase catalytic subunit |
| Inheritance | Autosomal dominant |
| Age of Onset | Typically 30-60 years (mean ~45) |

Key Pathogenic Mutations

Over 300 pathogenic mutations in PSEN1 have been identified. The most well-characterized include:

| Mutation | Location | Effect | Year Described |
|----------|----------|--------|----------------|
| M146L | TM2 | γ-secretase hyperactivity | 1995 |
| L286V | TM7 | Aβ42/40 ratio increase | 1998 |
| A246E | TM6 | Altered APP processing | 1996 |
| H163Y | TM4 | Increased Aβ42 | 1997 |
| L173W | TM4 | Impaired gamma-secretase | 2001 |
| C410Y | PALM | Loss of function | 2004 |
| P436S | PALM | Impaired autophagy | 2018 |

Genetic Evidence Score: 10/10

• Causality strength: Absolutely proven - PSEN1 mutations are fully penetrant causes of autosomal dominant AD
• Population frequency: Very rare (<0.001% of population)
• Age of onset: Highly predictable (~45 years average)
• Segregation: Perfect Mendelian inheritance in affected families

Molecular Mechanism

Gamma-Secretase Complex

PSEN1 is the catalytic core of the gamma-secretase complex, which includes:

Amyloid Beta Production Pathway

PSEN1 mutations alter the gamma-secretase cleavage pattern, leading to:

Downstream Molecular Effects

Cellular Mechanisms

Synaptic Dysfunction

PSEN1 mutations contribute to synaptic failure through:

• Aβ-induced synaptic pruning - Oligomeric Aβ42 drives excessive NMDA receptor internalization
• Calcium dysregulation - ER calcium leak through mutant presenilin
• Synaptic protein trafficking - Altered vesicular trafficking to synapses
• Long-term potentiation impairment - Memory trace weakening

Neuronal Death Pathways

Glial Cell Interactions

• Microglial activation - Aβ42 plaques trigger chronic neuroinflammation
• Astrocyte reactivity - Glial fibrillary acidic protein (GFAP) upregulation
• Neuroimmune axis - TREM2-expressing microglia attempt phagocytosis

Clinical Phenotype

Disease Progression

| Stage | Age | Clinical Features |
|-------|-----|-------------------|
| Preclinical | 30-40 | Normal cognition, biomarker changes |
| Prodromal | 40-45 | MCI, episodic memory deficits |
| Mild AD | 45-50 | Working memory impairment, word-finding difficulty |
| Moderate AD | 50-55 | Disorientation, behavioral changes |
| Severe AD | 55+ | Global cognitive decline, motor symptoms |

Phenotypic Heterogeneity

PSEN1 mutations show significant phenotypic variation:

• Ataxia - Some mutations (e.g., P436S) cause cerebellar ataxia
• Myoclonus - Seizure-like muscle jerks common in later stages
• Language predominant - Some families show primary progressive aphasia
• Atypical parkinsonism - Rare cases with Lewy body pathology

Therapeutic Intervention Points

Current Therapeutic Strategies

| Intervention | Mechanism | Development Stage | Target |
|--------------|-----------|-------------------|--------|
| Gamma-secretase modulators (GSMs) | Shift cleavage to produce less Aβ42 | Phase 2/3 | Aβ42 production |
| Anti-Aβ antibodies | Passive immunization against Aβ42 | Phase 3 (lecanemab, donanemab) | Aβ plaques |
| Aβ oligomer inhibitors | Block toxic oligomer formation | Preclinical | Aβ42 oligomers |
| BACE inhibitors | Prevent Aβ production upstream | Halted (toxicity) | BACE1 |
| PSEN1 correctors | Restore normal gamma-secretase function | Preclinical | PSEN1 folding |

Gene-Specific Therapies

| Approach | Strategy | Challenges | Timeline |
|----------|----------|------------|----------|
| ASO therapy | Silence mutant PSEN1 allele | Allele-specific targeting required | 5-10 years |
| CRISPR-Cas9 | Correct mutation in neurons | CNS delivery, off-target effects | 10+ years |
| Gene therapy | Deliver wild-type PSEN1 | Promiscuous gamma-secretase functions | 10+ years |
| Protein folding drugs | Correct PSEN1 misfolding | Small molecule delivery to brain | 5-10 years |

Intervention Point Diagram

Evidence Scores

| Category | Score | Rationale |
|----------|-------|-----------|
| Genetic Causality | 10/10 | Fully penetrant, autosomal dominant, >300 mutations |
| Mechanism Validation | 9/10 | Gamma-secretase complex well-characterized |
| Therapeutic Potential | 7/10 | Multiple approaches in development, but gamma-secretase complexity is challenging |
| Clinical Translation | 8/10 | Biomarkers available, clinical trials ongoing |
| Overall | 8.5/10 | Strong evidence for causal chain |

Cross-Disease Synthesis

Alzheimer's Disease Subtypes

• Early-onset familial AD: PSEN1 accounts for ~70% of FAD cases
• Late-onset AD modifier: PSEN1 variants may modify risk in LOAD
• Atypical AD: Some PSEN1 mutations cause posterior cortical atrophy

Cross-Disease Connections

| Disease | Connection | Evidence |
|---------|------------|----------|
| Parkinson's Disease | PSEN1 affects alpha-synuclein processing | Moderate |
| FTD | Shared neuroinflammation pathways | Moderate |
| ALS | TDP-43 co-pathology in some cases | Weak |
| Cerebral amyloid angiopathy | Aβ42 vascular deposition | Strong |

Shared Mechanisms with Other Neurodegeneration

• Protein aggregation - Similar to α-synuclein (PD), TDP-43 (ALS)
• ER stress - Shared with ALS (C9orf72, SOD1)
• Mitochondrial dysfunction - Universal feature across neurodegenerative diseases

Knowledge Gaps and Research Priorities

Unresolved Questions

High-Priority Research Areas

| Priority | Research Area | Rationale |
|----------|---------------|-----------|
| 1 | GSM development | Nearest to clinical translation |
| 2 | Biomarker discovery | Essential for clinical trials |
| 3 | Non-amyloid mechanisms | May reveal new targets |
| 4 | Gene therapy approaches | Potential cure |

References